HBM Healthcare Investments

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Chemomab Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on discovering innovative treatments for fibrosis-related diseases that have significant unmet medical needs. Chemomab's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of CCL24, a soluble protein that plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently under clinical development, with a particular emphasis on treating orphan diseases such as Primary Sclerosing Cholangitis and Systemic Sclerosis. The company is conducting three Phase 2 clinical trials for CM-101 in various fibrotic indications and anticipates reporting results from these studies in the near future.

Cartesian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in the United States that focuses on developing innovative cell and gene immunotherapies for the treatment of cancer and autoimmune diseases. The company specializes in chimeric antigen receptor therapies aimed at addressing conditions such as multiple myeloma. Utilizing its ImmTOR immune tolerance platform, Cartesian Therapeutics seeks to foster antigen-specific immunity while reducing adverse immune responses. The company employs proprietary technology and a manufacturing platform to deliver mRNA molecules into cells, enhancing their functionality without the risk of integrating into the cell's genetic material, as mRNA naturally degrades over time.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Vicore Pharma is a clinical-stage pharmaceutical company dedicated to developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company's lead drug candidate, C21, is a small molecule angiotensin II type 2 receptor agonist currently in phase 2a development and has received orphan drug designation in both the EU and the US. C21 is also being explored for potential applications in other rare diseases associated with the AT2 receptor. In addition to its pharmacological efforts, Vicore Pharma is developing Almee, an investigational medical device that employs cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. The company operates from Astra Zeneca’s Bioventurehub in Mölndal.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Numab is a biotechnology company focused on developing antibody-based therapeutics for severe diseases, including chronic inflammation and cancer. The company employs a plug-and-play platform that minimizes the randomness typically associated with the drug discovery process, allowing for the predictable creation of multispecific biotherapeutics. This platform facilitates the development of mono- or multispecific antibody fragment-based therapeutics with customized pharmacokinetic properties, enabling the healthcare sector to address multiple therapeutic targets simultaneously. Through its innovative approach, Numab aims to enhance the effectiveness of immunotherapies in treating complex medical conditions.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Mahzi Therapeutics is a biotechnology company founded in 2020 and based in San Mateo, California. The company is dedicated to addressing under-served rare genetic neurodevelopmental disorders through biopharmaceutical research, development, and manufacturing. By focusing on these rare diseases, Mahzi Therapeutics aims to contribute to the healthcare industry's ability to provide effective treatments for patients with significant unmet medical needs.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

ValCare, Inc. is a medical device company founded in 2012 and located in Irvine, California. The company specializes in designing and developing innovative devices and accessories for the minimally invasive treatment of heart valve disease, particularly focusing on mitral and tricuspid regurgitation. ValCare's transcatheter technology functions as a docking station for replacement prostheses and as a tool for mitral annulus repair, facilitating advanced treatment options for patients with heart disorders. This approach aims to enhance recovery times and improve patient outcomes in the management of heart valve conditions.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Vascular Dynamics, Inc. is a privately-held medical technology company founded in 2008 and based in Irvine, California. The company specializes in developing catheter-delivered implants for the treatment of drug-resistant hypertension. Its primary product, MobiusHD, utilizes a minimally invasive procedure to enhance the body's natural baroreceptor response in the carotid sinus, promoting vasodilation, lowering heart rate, modulating kidney response, and ultimately reducing blood pressure. Vascular Dynamics aims to provide effective treatment options for patients at risk of severe health conditions associated with high blood pressure, such as heart disease, stroke, and kidney disease. The team at Vascular Dynamics has over 75 years of combined experience in medical device development and commercialization.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Odyssey Therapeutics is a biotechnology company focused on developing next-generation immunomodulators and oncology drugs. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, identifying promising targets while reducing the likelihood of failure during development. Odyssey Therapeutics is committed to advancing the field of drug discovery and expediting clinical development, ultimately contributing to the creation of more effective precision medicines for the healthcare industry.

Vascular Dynamics, Inc. is a privately-held medical technology company founded in 2008 and based in Irvine, California. The company specializes in developing catheter-delivered implants for the treatment of drug-resistant hypertension. Its primary product, MobiusHD, utilizes a minimally invasive procedure to enhance the body's natural baroreceptor response in the carotid sinus, promoting vasodilation, lowering heart rate, modulating kidney response, and ultimately reducing blood pressure. Vascular Dynamics aims to provide effective treatment options for patients at risk of severe health conditions associated with high blood pressure, such as heart disease, stroke, and kidney disease. The team at Vascular Dynamics has over 75 years of combined experience in medical device development and commercialization.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

1000Farmacie is a prominent pharmacy marketplace in Italy that operates an online shopping platform dedicated to providing a diverse selection of pharmaceutical products. By collaborating with a network of independent pharmacies, the company ensures that customers can purchase healthcare items at competitive prices. The platform offers the convenience of same-day delivery to specified locations, enabling users to save both time and money while accessing essential health products.

Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

ConnectRN, Inc. operates an online platform that connects healthcare providers, such as hospitals and clinics, with qualified nurses seeking employment. Founded in 2014 and based in Newton, Massachusetts, the platform streamlines communication between nurse managers and nursing staff through a web dashboard and an alert system that notifies nurses of available shifts on their mobile devices. This tech-enabled network not only facilitates the filling of open positions in healthcare facilities but also fosters a supportive community for nurses, enhancing their access to job opportunities and professional support.

SK biopharmaceuticals aims to become a top tier specialty pharmaceutical company with global new drugs & innovative pipeline in CNS / metabolic disorders and to provide world class specialized pharmaceutical manufacturing services.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.

Ignis Therapeutics is a life science company focused on developing innovative therapies for central nervous system (CNS) conditions. The company aims to transform the treatment paradigm by advancing new therapeutic options that significantly enhance patient outcomes. Ignis Therapeutics is committed to improving the lives of patients by providing additional choices for physicians, thereby addressing unmet medical needs in the CNS field.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases. Using modern machine learning techniques, Odyssey is transforming the landscape of autoimmune treatments. Odyssey Therapeutics was founded in 2018 and is based in San Francisco, California.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.

Mahzi Therapeutics is a biotechnology company founded in 2020 and based in San Mateo, California. The company is dedicated to addressing under-served rare genetic neurodevelopmental disorders through biopharmaceutical research, development, and manufacturing. By focusing on these rare diseases, Mahzi Therapeutics aims to contribute to the healthcare industry's ability to provide effective treatments for patients with significant unmet medical needs.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company employs a proprietary platform to create conditionally active biologics (CABs), which enhance targeting of cancerous tissues while minimizing effects on normal cells, thereby improving safety and efficacy. BioAtla's lead product candidate, BA3011, is a conditionally active biologic designed to treat soft tissue and bone sarcomas, non-small cell lung cancer, and other tumors. The company is also advancing BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, aimed at multiple cancer types including renal cell carcinoma and hepatocellular carcinoma. With over 150 patents and applications, BioAtla's innovative approach expands the potential for treating previously untreatable cancers and enhances the manufacturability of its drug candidates.

C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.

CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Numab is a biotechnology company focused on developing antibody-based therapeutics for severe diseases, including chronic inflammation and cancer. The company employs a plug-and-play platform that minimizes the randomness typically associated with the drug discovery process, allowing for the predictable creation of multispecific biotherapeutics. This platform facilitates the development of mono- or multispecific antibody fragment-based therapeutics with customized pharmacokinetic properties, enabling the healthcare sector to address multiple therapeutic targets simultaneously. Through its innovative approach, Numab aims to enhance the effectiveness of immunotherapies in treating complex medical conditions.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

ConnectRN, Inc. operates an online platform that connects healthcare providers, such as hospitals and clinics, with qualified nurses seeking employment. Founded in 2014 and based in Newton, Massachusetts, the platform streamlines communication between nurse managers and nursing staff through a web dashboard and an alert system that notifies nurses of available shifts on their mobile devices. This tech-enabled network not only facilitates the filling of open positions in healthcare facilities but also fosters a supportive community for nurses, enhancing their access to job opportunities and professional support.

Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Neurelis is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for epilepsy and the broader central nervous system (CNS) market. Founded in 2007 and based in Encinitas, California, Neurelis aims to address unmet medical needs through a differentiated approach that leverages novel technologies. The company's platform enhances drug delivery and therapeutic benefits across a variety of molecules, including therapeutic proteins, peptides, and small and large non-peptide molecules. By applying its expertise in neuroscience, Neurelis seeks to improve patient care and optimize treatment outcomes for individuals with epilepsy and other CNS disorders.

ValCare, Inc. is a medical device company founded in 2012 and located in Irvine, California. The company specializes in designing and developing innovative devices and accessories for the minimally invasive treatment of heart valve disease, particularly focusing on mitral and tricuspid regurgitation. ValCare's transcatheter technology functions as a docking station for replacement prostheses and as a tool for mitral annulus repair, facilitating advanced treatment options for patients with heart disorders. This approach aims to enhance recovery times and improve patient outcomes in the management of heart valve conditions.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics that enhance the body’s immune response to cancer. Founded in 2017, the company utilizes its proprietary PREDATOR platform to engineer conditionally activated molecules, known as INDUKINE molecules. These therapeutics are designed to remain inactive in peripheral tissues but activate selectively within the tumor microenvironment, addressing the limitations of traditional proinflammatory immune therapies. By stimulating both adaptive and innate immunity, Werewolf Therapeutics aims to improve cancer treatment outcomes.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Instil Bio is a clinical-stage biotechnology company based in Dallas, Texas, focused on developing and commercializing tumor infiltrating lymphocyte (TIL) therapies for the treatment of solid tumors. The company specializes in utilizing a patient's own T cells, which are harvested from their tumor, expanded, and reinfused to target and eliminate cancer cells. Instil Bio is advancing its proprietary manufacturing technology and has initiated clinical trials, including a planned registrational study for its TIL candidate. Additionally, the company is developing a novel class of genetically engineered TIL therapies through its Co-Stimulatory Antigen Receptor (CoStAR) platform. One of its key pipeline products, ITIL-306, is designed to target FRα, a tumor-associated antigen present in various solid tumors such as ovarian cancer, uterine cancer, non-small cell lung cancer, and renal cancer.

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company specializes in the research and development of various drug delivery methods, including capsules, injections, and tubes. In addition to its focus on drug development, Nuance Biotech offers a commercial and academic platform for pharmaceuticals and provides contract sales organization services to support its initiatives in the healthcare sector.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Everlife Asia is a buy-and-build platform aimed to provide complete solutions for the healthcare and research industries.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for neurological diseases. The company's proprietary pipeline includes several product candidates, notably LP352, a next-generation 5-HT2C agonist intended for treating developmental and epileptic encephalopathies. Additionally, Longboard is evaluating LP143, a full agonist of the cannabinoid type 2 receptor, which targets conditions such as amyotrophic lateral sclerosis and Parkinson's disease, as well as LP659, a selective modulator for multiple central nervous system neuroinflammatory disorders. Longboard Pharmaceuticals aims to optimize pharmacology and pharmacokinetics across its drug candidates, enhancing therapeutic outcomes for patients with rare neurological conditions. The company was incorporated in 2020 and was previously known as Arena Neuroscience, Inc.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Neurelis is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for epilepsy and the broader central nervous system (CNS) market. Founded in 2007 and based in Encinitas, California, Neurelis aims to address unmet medical needs through a differentiated approach that leverages novel technologies. The company's platform enhances drug delivery and therapeutic benefits across a variety of molecules, including therapeutic proteins, peptides, and small and large non-peptide molecules. By applying its expertise in neuroscience, Neurelis seeks to improve patient care and optimize treatment outcomes for individuals with epilepsy and other CNS disorders.

BioShin Limited is a clinical-stage biopharmaceutical company based in Pudong, China, focused on developing innovative medicines and therapies for neurological, neuropsychiatric diseases, and rare disorders. Established in 2018, it operates as a wholly owned subsidiary of Biohaven Pharmaceuticals. The company specializes in late-stage product candidates and utilizes clinical trial platforms to explore treatments such as calcitonin gene-related peptide (CGRP) receptor antagonism for migraine and pain, glutamate modulation for Alzheimer’s disease and anxiety disorder, and myeloperoxidase (MPO) inhibition for inflammation and neurodegeneration. BioShin aims to address unmet medical needs in the neurological field, particularly within the Asia-Pacific market.

Galecto is a clinical-stage biotechnology company focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company’s lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 aimed at addressing severe fibrotic lung diseases, including idiopathic pulmonary fibrosis, which presents a significant unmet medical need. Founded in 2011, Galecto builds upon more than a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company also develops additional therapeutics, such as GB1211, a selective oral galectin-3 inhibitor targeting fibrosis related to non-alcoholic steatohepatitis. Galecto's strong patent portfolio and research foundation position it uniquely within the therapeutic landscape for fibrosis and related diseases.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Polyneuron Pharmaceuticals AG is a biotechnology company based in Basel, Switzerland, founded in 2014. The company focuses on developing innovative therapeutics for antibody-mediated autoimmune disorders, particularly those affecting the peripheral nervous system. Its lead candidates include PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron employs a unique platform technology called Antibody-Catch, which utilizes biodegradable glycopolymers to selectively target and eliminate pathogenic autoantibodies while preserving the overall integrity of the immune system. This approach aims to provide safe and effective treatment options for patients suffering from these complex immune disorders.

NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Sublimity Therapeutics is a specialty pharmaceutical company focused on developing therapies for gastrointestinal and immunological diseases. Based in Dublin, Ireland, and Solana Beach, California, the company aims to address unmet clinical needs with its innovative drug delivery technology. Sublimity's product portfolio includes therapies like STI-0529 for moderate to severe ulcerative colitis, CyCron for Crohn's disease, and AlloCol for graft versus host disease prevention and treatment. Additionally, it offers a range of oral formulations, including SmPill products for conditions such as colon cancer and inflammatory bowel disease, as well as oral vaccines and peptides. The company’s proprietary technology enhances the oral delivery of challenging drugs, improving their solubility and bioavailability, thereby enabling targeted treatment within the gastrointestinal tract.

Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company employs a proprietary platform to create conditionally active biologics (CABs), which enhance targeting of cancerous tissues while minimizing effects on normal cells, thereby improving safety and efficacy. BioAtla's lead product candidate, BA3011, is a conditionally active biologic designed to treat soft tissue and bone sarcomas, non-small cell lung cancer, and other tumors. The company is also advancing BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, aimed at multiple cancer types including renal cell carcinoma and hepatocellular carcinoma. With over 150 patents and applications, BioAtla's innovative approach expands the potential for treating previously untreatable cancers and enhances the manufacturability of its drug candidates.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Everest Medicines Limited is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2017. The company focuses on licensing, developing, and commercializing innovative therapies to meet critical unmet medical needs in Greater China and other Asia Pacific markets. Its diverse portfolio includes eight clinical-stage drug candidates aimed at treating various conditions such as oncology, immunology, cardio-renal diseases, and infectious diseases. Everest Medicines aims to partner with innovative global companies to bring transformative pharmaceutical solutions to the Emerging Market, leveraging its expertise in clinical development, regulatory affairs, and business operations. The company's pipeline features several notable candidates, including Nefecon, EVER001, PTX-COVID19-B, and Eravacycline, among others.

Jianke is anonline B2C pharmacy and healthcare services platform.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

Genalyte, Inc. is a clinical and diagnostic life science company that specializes in rapid diagnostic testing solutions for healthcare providers and researchers. Founded in 2007 and based in San Diego, California, Genalyte has developed the Maverick platform, which utilizes silicon photonics technology to directly measure the binding of biomolecules, such as antibodies and proteins, to silicon photonic biosensors. This innovative approach allows for the quick detection of various health conditions, including autoimmune diseases, cancer biomarkers, and infectious agents. The company’s systems enable mobile laboratories to deliver real-time diagnostics in under thirty minutes, enhancing the quality of care while optimizing resource use within the healthcare system.